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Abstract
Background: The National AIDS control programme (NACP) in India is currently following the World Health Organization
(WHO) 2010 antiretroviral therapy (ART) guidelines. In 2013, the WHO revised its recommendations for initiating ART among
people living with HIV (PLHIV) by increasing the threshold for ART initiation to a CD4 count #500 cells/uL. For certain
patient groups, ART is recommended irrespective of CD4 count (PLHIV with active tuberculosis, hepatitis B virus infection,
pregnant and breast feeding women, children aged under five years and those living in a sero-discordant relationship). In
this operational research, we assess the effect of applying this recommendation on the number of PLHIV additionally
eligible for ART.
Methods: This was a cross-sectional analysis of routinely collected programme data from all PLHIV registered in Karnataka
State (population 60 million), India in 2012.
Results: Of 37,044 PLHIV, 27,074 (73%) were eligible for initiating ART as per WHO-2010 criteria. As per the WHO-2013
criteria (CD4 count #500 and all pregnant women and under-five children irrespective of CD4 count), an additional 5104
(14%) HIV-infected people would be eligible for initiating ART. There were no data to inform the additional patient load due
to sero-discordance.
Conclusion: Adopting the WHO-2013 guidelines for India has important resource implications. However, given the
significant patient and programmatic benefits of adopting the new guidelines, this has been considered favourably by the
NACP in India and steps are being planned to integrate ART care into the general health system to cope with the increased
numbers of patients.
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Introduction
With the progress in the scale-up and access to free
antiretroviral therapy (ART) across the globe, Human Immuno-
deficiency Virus (HIV) infection, has now become a chronic
manageable illness rather than a virtual death sentence a decade
ago [1]. HIV incidence and mortality are declining steadily [1].
However, with an estimated 34 million people living with HIV
(PLHIV), 2.4 million new HIV infections and 1.7 million deaths in
2011, HIV continues to be the most common infectious cause of
mortality in the world, with sub-Saharan Africa being its epicentre
[1]. India is considered a country with a concentrated HIV
epidemic and contributes to about 10% of the global burden in
absolute terms [1]. The HIV epidemic in India is showing a
declining trend and in 2011, about 2.1 million people were living
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with HIV in India with an estimated 0.12 million new infections
and 0.15 million deaths [2].
ART is the most important life-saving intervention for PLHIV.
HIV is probably the only infectious disease where there is a
waiting period before treatment is initiated. This has been for
various reasons that include the toxic nature of the ARV drugs,
concerns about non-adherence and risk of drug resistance if
treatment is started too early and the need to weigh up benefits
and harms of starting treatment at certain CD4 count thresholds.
The first guidance from WHO in 2002 recommended ART for
those in WHO clinical stage 3 and 4 and those with a CD4
lymphocyte count of #200 cells/uL. With availability of safer and
inexpensive treatment options and evidence of benefit of earlier
ART in terms of reduced morbidity and mortality, WHO raised
the CD4 cut-off for starting ART to#350 cells/uL in 2010. In the
first ever consolidated guidelines on the use of antiretroviral drugs
published in 2013, the WHO recommends to further raise the
threshold for ART initiation to a CD4 count #500 cells/uL in
adults, adolescents and children aged five years and above. For
certain patient groups, ART is recommended irrespective of CD4
count e.g. PLHIV having active TB disease, hepatitis B virus
infection with severe chronic liver disease, pregnant and breast
feeding women, children aged under five years, and those living in
a sero-discordant relationship to reduce HIV transmission to
uninfected partners (Table 1) [3]. This decision comes in the
wake of recent and growing evidence of the benefits of starting
ART early, with the potential for reducing HIV-related morbidity
and mortality and preventing onward transmission of HIV. Thus,
early initiation of ART has both individual clinical benefits and
population level benefits.
The National AIDS control programme (NACP) in India is
currently following the WHO 2010 ART guidelines [4]. Adoption
of the new WHO recommendations is likely to increase the
number of PLHIV eligible for ART in India and there are
concerns that it may pose an increased burden on the NACP as
well as the general health system. However, currently there is no
information on the number and proportion of PLHIV that will be
additionally eligible for ART if the NACP decides to adopt 2013
WHO guidelines. This information is critical for programme
planning including forecasting of drug requirements, procurement
and supply chain management of new formulations of drugs and
possible changes in delivery of ART services within health systems
to cope with increased numbers of people receiving ART. In this
operational research, we therefore aimed to assess the number of
PLHIV who were additionally eligible for ART in a large south
Indian state of Karnataka. The specific objective was to determine
among a cohort of PLHIV registered for HIV care in the year
2012 in Karnataka, the number (proportion) eligible for ART if
the WHO 2013 ART guidelines were followed.
Methods
Ethics considerations
Ethics approval was obtained by the Ethics Advisory Group of
International Union Against Tuberculosis and Lung Disease,
Paris, France. Administrative approval to conduct the study was
obtained from the National AIDS Control Organization in India.
Since this was a retrospective review of existing records and did
not involve any direct patient interaction, ethics committee waived
the need for individual informed consent.
Study Design
This was a cross-sectional study involving secondary analysis of
data routinely recorded under the National AIDS Control
Programme (NACP).
Setting
Karnataka, with 30 districts and a population of 61 million, is
one of four large states in South India facing a relatively advanced
HIV epidemic, with the adult HIV prevalence in some districts
Table 1. Comparison of WHO guidelines for ART initiation among people living with HIV in the year 2010 and 2013.
Population Target Population 2010 ART guidelines 2013 ART guidelines
Adults and Adolescents HIV infected individuals CD4 count ,350 cells/mm3 or WHO clinical
stage 3 or 4 regardless of CD4 cell count
CD4 count #500 cells/mm3 or
WHO clinical stage 3 or 4 regardless of
CD4 cell count
Adults and Adolescents HIV infected pregnant and
breastfeeding women
CD4 count #350 cells/mm3 regardless of clinical
symptoms or WHO clinical stage 3 or 4
regardless of CD4 cell count
Regardless of CD4 cell count or
WHO clinical stage
Adults and Adolescents HIV infected partners in
serodiscordant couple relationship(s)
No recommendation established Regardless of CD4 cell count or
WHO clinical stage
Adults and Adolescents HIV/TB co-infection Presence of active TB disease, regardless of CD4 cell count No change
Adults and Adolescents HIV/HBV co-infection Evidence of chronic active HBV disease,
regardless of CD4 cell count
Evidence of chronic HBV disease
with advanced stage liver disease
(e.g. cirrhosis), regardless of CD4
cell count
Children HIV infected children $5 years old CD4 #350 cells/mm3 or WHO clinical stage 3 or 4
regardless of CD4 cell count
CD4 count #500 cells/mm3 or
WHO clinical stage 3 or 4 regardless of
CD4 cell count
Children HIV infected children 1–5 years old 1. Between 12 and 24 months of age, regardless of
CD4 count or WHO clinical stage. 2. Between 24
and 59 months of age with CD4 count of #750 cells/mm3
or CD4% #25, or whichever is lower, regardless of
WHO clinical stage.
Regardless of CD4 cell count and
clinical stage
Children HIV infected infants ,1 year old All infants, regardless of CD4 cell count and clinical stage No change
WHO-World Health Organization; ART-antiretroviral therapy; HIV-Human immunodeficiency virus; TB – Tuberculosis; HBV – Hepatitis B Virus.
doi:10.1371/journal.pone.0107136.t001
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exceeding 1%. According to national estimates in 2012,
Karnataka state had a HIV-prevalence of 0.52% with 0.21 million
persons living with HIV [5].
There were 565 stand-alone HIV testing facilities, 1050 facility
integrated HIV testing facilities and 49 ART centers in the State.
The primary aim of the HIV testing facilities is to provide
information, counselling and HIV testing services. All HIV
positive persons diagnosed at testing centres are referred to the
nearest ART centre for further management. HIV positive
patients, who reach ART centres are registered for HIV care,
are assessed clinically as per WHO clinical staging including CD4
count assessments and if found eligible for ART according to
national guidelines, they are initiated on ART [6,7]. Most of the
ART centres are situated in tertiary care facilities and all
supportive patient care, like investigations or facilities for
hospitalization, is integrated within the general health system.
India currently follows WHO 2010 ART guidelines. All services
including diagnosis of HIV, CD4 count assessments and ART are
provided free of cost for the patients.
Study population and Study period
All PLHIV newly diagnosed and registered for HIV care at
ART centres in Karnataka State in the year 2012 constituted the
study population. The study was conducted during the year 2013.
Data collection procedure and data variables
The data variables included pre-ART number, age, sex, WHO
clinical staging, CD4 lymphocyte count at the time of registration,
co-existing TB disease (Yes/No) and whether pregnant (Yes/No)
at the time of registration. These variables were extracted from the
electronic medical record maintained at the ART centres during
the month of August 2013. Original data sources for this record
included the pre-ART patient register and patient treatment cards
maintained at each centre.
Data entry and analysis
Since the data were already present in the electronic format,
double data entry and validation was not considered. Abstracted
data from the Microsoft Excel database were imported into
EpiData software and analysed (Version 2.2.2.182, EpiData
Association, Odense, Denmark).
Results
Of 49 ART centres in the State, data were available from 47
centres. Two ART centres which operated under a public-private
mix model and accounted for less than 0.5% of all PLHIV
registered in 2012 were not included due to lack of data. There
were 37,307 HIV-positive patients registered for HIV care (pre-
ART) in these centres. Basic demographic and clinical character-
istics of the study population are described in Table 2. Of all
HIV-infected people, 50% were males and the median (IQR) age
was 35 (28–42) years. About 6% were children (aged less than 15
years) and about 2% were aged less than five years. About 13%
had TB and 4% were pregnant at enrolment. The median (IQR)
CD4 count was 242 (122–415) and was significantly higher in
females [275(144–466)] as compared with males [208(106–361)].
About 75% were assessed to be in WHO clinical stage 1 or 2.
The number and proportion eligible for initiating ART as per
WHO-2010 guidelines and 2013 guidelines are compared in
Table 3. Of all PLHIV registered, eligibility could be assessed for
37044 (99%). As per the WHO-2010 criteria, 27074 (73%) were
eligible for initiating ART and nearly 85% of those eligible were
initiated on ART. As per the WHO-2013 criteria, an additional
5104 (14%) HIV-infected people would be eligible for initiating
ART if all recommendations on CD4 cell count, pregnant women
and children under-five years were followed, resulting in 87% in
total being eligible for treatment.
Discussion
This is the first study from India assessing the potential resource
implications of adopting the WHO 2013 ART guidelines.
Evidence from this large cohort of PLHIV from Karnataka state
provides programmatically useful information from a planning
perspective. Several points require further comment.
First, we found that nearly 90% of PLHIV would be eligible for
ART as per the new recommendations, an addition of about 15%
when compared to WHO 2010 recommendations. Adopting the
new strategy will require increases in costs, manpower, infrastruc-
ture and drug requirements and the logistics need to be carefully
planned to ensure smooth implementation of services [8]. In
addition to clinical and immunological benefits, early ART has
operational benefits too. Previous studies have shown better
patient retention among those who are ‘on ART’ as compared to
those who in ‘Pre-ART care’ [9]. So, adopting the new WHO
guidelines will be of benefit for both the patients and the
programme. Given the preparedness of the well-resourced NACP
in India, this should be feasible and a decision to adopt the new
WHO guidelines has been announced by the Union Health and
Family Welfare Minister in a recent press release [5].
Second, we could not assess how many PLHIV would be
eligible for ART if the criterion of sero-discordance was applied as
we did not capture this data on this aspect. Although
recommended by the NACP in India, information on HIV status
of partners was not systematically documented in the treatment
cards. We could not assess if it was merely due to poor
documentation or suboptimal uptake of HIV testing among the
partners. Previous studies analysing nationally representative data
from the National Family Health Survey – 3 have indicated that
among married couples with a HIV-infected partner; nearly 75%
were sero-discordant [10,11]. If we apply this figure to our cohort,
then nearly all PLHIV would be eligible for ART. From a public
health perspective, this would mean ‘immediate and universal
ART’ for every person with HIV and is in alignment with the
vision of NACP phase-IV for the period 2012–17 [5].
Third, implementation of the new strategy would mean that
many PLHIV would be started on ART, while they are still
asymptomatic and at higher CD4 counts. To avoid side-effects and
improve treatment adherence over the long term in such patients,
there will be a need to use tenofovir more frequently in the first
line regimens, as recommended in the 2013 WHO Guidelines,
which may further add to the costs.
Fourth, the current vertical structure of the programme (with
delivery of services through a centralized network of ART centres
with dedicated staff) may make it difficult to cope with the
increased demand for services that will arise due to the new policy.
While there have been some efforts by NACP in India to create a
network of ‘Link ART centres’ at sub-district level health facilities
to increase the access for PLHIV, this may not be sufficient.
Hence, innovative strategies for delivery of ART may be required,
such as further decentralisation of services, better integration and
linkage of services and task shifting of personnel, all of which are
broadly recommended by WHO. This will help in mitigating the
costs and is in line with the overall vision of the Government of
India to integrate NACP into the general health system [5].
There were a few limitations to our study. First, we did not
conduct a costing exercise to assess the cost implications of
Adopting the WHO 2013 ART Guideline in India
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Table 2. Demographic and clinical characteristics of HIV infected people registered for pre-ART care in Karnataka State, India, 2012
(N= 37307).
Characteristics Number Percentage
Sex
Male 18662 50.0
Female 18520 49.7
Transgender 85 0.2
Not recorded 40 0.1
Age in years
0–4 617 1.7
5–14 1560 4.2
15–24 3047 8.2
25–34 11284 30.2
35–44 12425 33.3
45–54 5776 15.5
55–64 1985 5.3
65 and above 575 1.5
Not recorded 38 0.1
Tuberculosis 4745 12.7
Pregnant women 1494 4.0
WHO Clinical staging
Stage 1 12677 34.0
Stage 2 15645 41.9
Stage 3 6642 17.8
Stage 4 1793 4.8
Unknown 550 1.5
CD4 Count
#50 3163 8.5
51–250 16072 43.1
251–350 5955 16.0
351–500 5219 14.0
501 and above 6491 17.4
Unknown 407 1.1
WHO-World Health Organization; ART-antiretroviral therapy; HIV-Human immunodeficiency virus;
doi:10.1371/journal.pone.0107136.t002
Table 3. Number of HIV-infected people eligible for ART as per the current and new WHO criteria for ART initiation, Karnataka
State, India, 2012 (N = 37044*).
Eligibility Criteria Number eligible Percentage Number (%) additionally eligible
WHO-2010 ART Guidelines 27074 73.1
WHO-2013 ART Guidelines (CD4 count #500) 31483 85.0 4409 (11.9)
WHO-2013 ART Guidelines (all pregnant women irrespective
of CD4 count)
27981 75.5 907 (2.4)
WHO-2013 ART Guidelines (all children under five years
irrespective of CD4 count)
27262 73.6 188 (0.5)
WHO-2013 ART Guidelines (CD4 count #500+all pregnant
women+ all under-five children irrespective of CD4 count)
32178 86.9 5104 (13.8)
WHO-World Health Organization; ART-antiretroviral therapy; HIV-Human immunodeficiency virus;
*Eligibility could not be assessed for 263 patients.
doi:10.1371/journal.pone.0107136.t003
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adopting the new strategy. A full economic assessment would have
added value to our findings but was beyond the scope of the
current effort. This is a major limitation and needs to be addressed
in future research. Second, this was an operational research and
relied on the routinely recorded data with its inherent limitations.
Third, we did not find data on HIV status of the partner and
HIV/Hepatitis B co-infection documented in the treatment cards.
Having this information would have helped in more accurate
estimation of ART eligibility. Fourth, while the study used a large
cohort, it came from one state in South India and cannot be
claimed to be nationally representative. So, similar analyses should
be conducted from other states or in a nationally representative
sample before the findings can be generalized.
In conclusion, transitioning to the WHO 2013 ART guidelines
in India would virtually mean ‘immediate and universal ART’ for
all PLHIV with substantial resource implications. However, given
the significant patient and programmatic benefits of adopting the
new guidelines, this has been considered favourably by the NACP
in India and steps are being planned to integrate ART care into
the general health system to cope with the increased numbers of
patients.
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